{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:27:54Z","timestamp":1774441674299,"version":"3.50.1"},"reference-count":48,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["DSE\u2010146021"],"award-info":[{"award-number":["DSE\u2010146021"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To describe the prescribing trends of 17 therapeutic drug categories and the specific drug classes of systemic antibiotics, analgesics, and antidepressants in children and adolescents in the United Kingdom between 1998 and 2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A population\u2010based retrospective cohort study including children and adolescents aged 018\u2009years. Overall and annual prescription rates per 10\u2009000 person\u2010years and corresponding 95% confidence intervals (CIs) were calculated. Rate ratios and 95% CIs were calculated to assess changes in prescription rates during the study period using Poisson regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 4\u2009075\u2009527 children and adolescents during the study period from 1998 to 2018, the prescribing rates increased by 15% for attention deficit hyperactivity disorder drugs (rate ratio: 1.15, 95% CI: 1.12\u20131.18), 14% for anxiolytics and hypnotics (rate ratio: 1.14, 95% CI: 1.13\u20131.16), and 8% for drugs for gastroesophageal reflux disease (GERD) (rate ratio: 1.08, 95% CI: 1.07\u20131.09). Prescribing rates decreased by 6% for cough preparations (rate ratio: 0.94, 95% CI: 0.92\u20130.95) and by 3% for analgesics (rate ratio: 0.97, 95% CI: 0.96\u20130.99). No meaningful changes were observed for systemic antibiotics (rate ratio: 1.02, 95% CI: 0.99\u20131.04). Among specific drug classes, prescribing rates decreased for broad\u2010spectrum penicillins and cephalosporins, and they increased for selective serotonin reuptake inhibitors, opioids, and drugs for migraine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Between 1998 and 2018, the prescribing of centrally acting drugs and drugs for GERD increased among pediatric patients, whereas prescribing of cough preparations and analgesics declined in this population.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5377","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T10:09:11Z","timestamp":1635415751000},"page":"302-313","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["General practitioner prescribing trends among pediatric patients in the United Kingdom: 1998\u20132018"],"prefix":"10.1002","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3949-3909","authenticated-orcid":false,"given":"Reem","family":"Masarwa","sequence":"first","affiliation":[{"name":"Centre for Clinical Epidemiology Lady Davis Institute, Jewish General Hospital  Montreal Quebec Canada"},{"name":"Department of Epidemiology, Biostatistics, and Occupational Health McGill University  Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Centre Hospitalier Universitaire Ste\u2010Justine University of Montreal  Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5981-8443","authenticated-orcid":false,"given":"Robert W.","family":"Platt","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology Lady Davis Institute, Jewish General Hospital  Montreal Quebec Canada"},{"name":"Department of Epidemiology, Biostatistics, and Occupational Health McGill University  Montreal Quebec Canada"},{"name":"Department of Pediatrics McGill University  Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6055-0088","authenticated-orcid":false,"given":"Kristian B.","family":"Filion","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology Lady Davis Institute, Jewish General Hospital  Montreal Quebec Canada"},{"name":"Department of Epidemiology, Biostatistics, and Occupational Health McGill University  Montreal Quebec Canada"},{"name":"Department of Medicine McGill University  Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.13766"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2015.4276"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7199.1668"},{"key":"e_1_2_10_5_1","volume-title":"Promoting safety of medicines for children","author":"The World Health Organization","year":"2007"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acap.2008.11.010"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035092"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1284"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1059840516641190"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.23.2847"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-1958"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyt261"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081671"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-2879"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.5690"},{"issue":"6","key":"e_1_2_10_16_1","first-page":"1360","article-title":"Prescribing pattern of antipsychotic drugs during the years 1996\u20102010: a population\u2010based database study in Europe with a focus on torsadogenic drugs","volume":"83","author":"Oteri A","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-13-192"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022979"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a2245"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04063.x"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13000"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010508"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq452"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2007.119834"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00701.x"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03537.x"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.5.686.32205"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp10X483562"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0923"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.329"},{"key":"e_1_2_10_32_1","unstructured":"HadleyW WinstonC LionelH et al. Create elegant data visualisations using the grammar of graphics; 2020. Accessed February 15 2020.https:\/\/cran.r-project.org\/web\/packages\/ggplot2\/ggplot2.pdf"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.3919"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40084"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-4060"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1977-x"},{"issue":"11","key":"e_1_2_10_37_1","first-page":"1","article-title":"Gender differences in outpatient pediatric drug utilization: a cohort study from southern Italy","volume":"10","author":"Ferrajolo C","year":"2019","journal-title":"Front Pharmacol"},{"key":"e_1_2_10_38_1","unstructured":"Agency MaHpR.Chief Medical Officer annual report 2011: antimicrobial resistance;2013. Accessed April 07 2020.https:\/\/www.gov.uk\/government\/publications\/chief-medical-officer-annual-report-volume-2"},{"key":"e_1_2_10_39_1","unstructured":"Agency MaHpR.Codeine for cough and cold: restricted use in children. Medicines and Healthcare products Regulatory Agency;2015. Accessed April 07 2020.https:\/\/www.gov.uk\/drug-safety-update\/codeine-for-cough-and-cold-restricted-use-in-children"},{"issue":"2","key":"e_1_2_10_40_1","first-page":"140","article-title":"Best pharmaceuticals for children act and pediatric research equity act: time for permanent status","volume":"17","author":"Christensen ML","year":"2012","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_2_10_41_1","unstructured":"FDA T.Suicidality in children and adolescents being treated with antidepressant medications;2004. Accessed April 07 2020.https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/suicidality-children-and-adolescents-being-treated-antidepressant-medications"},{"key":"e_1_2_10_42_1","unstructured":"FDA T.FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children. The FDA;2013. Accessed April 07 2020.https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-restricts-use-prescription-codeine-pain-and-cough-medicines-and"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eujim.2020.101136"},{"issue":"1","key":"e_1_2_10_44_1","first-page":"242","article-title":"Time trends and geographical variation in prescribing of antibiotics in England 1998\u20132017","volume":"74","author":"Curtis HJ","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001324"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2013.09.017"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.03.041"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2016-310716"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30269-4"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5377","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5377","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T18:35:41Z","timestamp":1692815741000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1002\/pds.5377"],"URL":"https:\/\/doi.org\/10.1002\/pds.5377","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]},"assertion":[{"value":"2021-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}